Business Wire

AI Takes Center Stage as the Major Threat to Cybersecurity in 2026

2.12.2025 12:00:00 CET | Business Wire | Press Release

Share

Experian® today released its 2026 Data Breach Industry Forecast, offering a look at the evolving cyber threat landscape. The predictions address how the coming year could usher in a new wave of sophisticated attacks driven by artificial intelligence along with other threats and vulnerabilities including quantum computing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202474758/en/

Experian's 2026 Data Breach Industry Forecast

Now in its 13th year, the forecast offers six insights into how cybercriminals are leveraging emerging technologies to create more convincing identities, evade detection, and exploit new digital frontiers. From synthetic profiles and autonomous AI agents to shape-shifting malware and even brain-computer interface vulnerabilities, the 2026 predictions point to a future where cyberattacks are more personalized, persistent, and technologically advanced than ever before.

To download the complimentary paper, go here.

“Technology is evolving at breakneck speed, and cybercriminals are often the first to adopt tools like AI to outpace defenses and exploit vulnerabilities,” said Michael Bruemmer, vice president of Global Data Breach Resolution at Experian. “It’s an uphill battle but organizations can also harness these same innovations to strengthen their security posture. With the right preparation and use of technology, companies can be in a solid position to combat attacks, but they should also be ready to deal with the fallout of a security incident.”

There have been more than 8,000 global data breaches in the first half of 2025 with approximately 345 million records exposedi. Among Experian clients, the top countries hit hardest are the United States, United Kingdom, and Canada.

“We’re entering a new era where cyberattacks are no longer just about stealing data, they’re about manipulating reality,” said Jim Steven, Head of Crisis and Data Response Services at Experian Global Data Breach Resolution in the United Kingdom. “Organizations must prepare for threats that are faster, smarter, and harder to detect. The time to act is now.”

To learn more about Experian Data Breach Resolution, attendees at the Financial Times Cyber Resilience Summit: Europe held at Convene in London can visit the Experian table and attend the panel discussion, “How can leaders combat emerging cyber security threats?” including Steven on December 3, 2025, at 4:50-5:30pm GMT.

Consumers Concerned about AI Impact

Experian research among consumers in the United States and United Kingdom shows that many are feeling the impact of savvy attacks and anxious about cyber threats worsening.

Additionally, findings reveal that younger generations are increasingly vulnerable to scams, while many victims feel unsupported after their data is compromised. Consumers question whether the companies they trust are ready to defend against sophisticated cyber threats. Overall, key findings include:

  • 1 in 4 millennial adults surveyed say they’ve been a victim of identity theft in the past year.
  • Nearly a quarter say they’ve fallen for a phishing attack at home or work in the past 12 months.
  • More than 4 in 5 are concerned about AI being used to create fake identities that are indistinguishable from real people.

Key U.S. findings:

  • More than one in three (35%) adults worry about being found personally liable for monetary loss as a result of a cybersecurity mistake at work.
  • 69% do not believe their bank or retailer is adequately prepared to defend against AI-driven cyberattacks or they’re unsure.
  • Over three-quarters (76%) believe that cybercrime will continue to increase and be impossible to slow down because of AI.

Top UK results:

  • A quarter of millennial adults (25%) say they’ve been a victim of identity theft in the past year.
  • One in three (33%) UK adults worry about damaging their professional reputation due to a cybersecurity mistake at work.
  • Among those who’ve had their data stolen or exposed in a data breach, more than 3 in 5 (62%) did not say the organization provided adequate support.

Experian Data Breach Resolution helps organizations respond swiftly and confidently to data breaches with over 21 years of crisis management expertise and more than 69,000 incidents served. Its comprehensive services include global consumer notifications, multilingual call centers, and identity protection tools like credit monitoring and dark web surveillance. Experian’s Reserved Response™ ensures readiness with guaranteed staffing and infrastructure, while its international capabilities support breach response across 100+ countries. Whether facing a live breach, third-party incident, or class action crisis, Experian delivers tailored solutions to protect customer trust and minimize reputational risk.

For more information about Experian Global Data Breach Resolution, go to https://www.experian.com/business/solutions/fraud-management/global-data-breach-services.

About Experian

Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics, and software. We also assist millions of people to realise their financial goals and help them to save time and money.

We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.

We invest in talented people and new advanced technologies to unlock the power of data and to innovate. A FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 25,100 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.

iData Breach Statistics 2025: Key Trends, Costs & Risks Revealed, SQ Magazine, October 6, 2025

View source version on businesswire.com: https://www.businesswire.com/news/home/20251202474758/en/

Contacts

MEDIA CONTACTS
Sandra Bernardo
Experian
1 949 529 7550
sandra.bernardo@experian.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye